Efficacy of Dexamethasone Implants in Uveitic Macular Edema in Cases with Behcet Disease

YALÇINBAYIR Ö. , Caliskan E., UÇAN GÜNDÜZ G. , Gelisken O., Kaderli B., YÜCEL A. A.

OPHTHALMOLOGICA, vol.241, no.4, pp.190-194, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 241 Issue: 4
  • Publication Date: 2019
  • Doi Number: 10.1159/000490674
  • Title of Journal : OPHTHALMOLOGICA
  • Page Numbers: pp.190-194


Purpose: Investigation of the efficacy of intravitreal dexamethasone implants (0.7 mg) in patients with Behcet disease (BD) who had cystoid macular edema (CME) despite immunomodulatory treatment. Materials and Methods: Twenty-seven eyes of 20 patients who had intravitreal dexamethasone implant injections and follow-up for more than 6 months were included in this study. Best corrected visual acuities (BCVA), intraocular pressures (IOP), and central macular thicknesses (CMT) were recorded. Systemic immunomodulatory treatment was noted. Injection-related complications and the need for recurrent injections were recorded. Results: Statistically significant anatomical and functional success was achieved with a single injection. BCVA increased from 0.85 +/- 0.72 to 0.45 +/- 0.52 logMAR, while the mean CMT decreased from 406 +/- 190 to 243 +/- 101 mu m at the sixth month. The peak of visual acuity gain was reached within the first 2 months and a substantial proportion of the patients gained 3 or more lines. There was no complication other than transient IOP elevation in 4 eyes and cataract surgery in 2 eyes. Conclusion: Adjuvant intravitreal dexamethasone implant injections offer promising results in cases of BD with CME. It is effective in preserving the macular anatomy and vision particularly in transition to biological agents. (C) 2018 S. Karger AG, Basel